학술논문
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study
Document Type
Article
Author
Basu, Partha; Muwonge, Richard; Bhatla, Neerja; Nene, Bhagwan M.; Joshi, Smita; Esmy, Pulikottil O.; Poli, Usha Rani Reddy; Joshi, Geeta; Verma, Yogesh; Zomawia, Eric; Shastri, Surendra S.; Pimple, Sharmila; Anantharaman, Devasena; Prabhu, Priya R.; Hingmire, Sanjay; Sauvaget, Catherine; Lucas, Eric; Pawlita, Michael; Gheit, Tarik; Jayant, Kasturi; Malvi, Sylla G.; Siddiqi, Maqsood; Michel, Angelika; Butt, Julia; Sankaran, Subha; Rameshwari Ammal Kannan, Thiraviam Pillai; Varghese, Rintu; Divate, Uma; Willhauck-Fleckenstein, Martina; Waterboer, Tim; Müller, Martin; Sehr, Peter; Vashist, Shachi; Mishra, Gauravi; Jadhav, Radhika; Thorat, Ranjit; Tommasino, Massimo; Pillai, M. Radhakrishna; Sankaranarayanan, Rengaswamy
Source
Papillomavirus Research; June 2019, Vol. 7 Issue: 1 p75-81, 7p
Subject
Language
ISSN
24058521
Abstract
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15–18 years of age (Bhatla et al., 2018) [7].